Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in Scand J Gastroenterol

Retrieve available abstracts of 24 articles:
HTML format



Single Articles


    June 2021
  1. WALDENSTROM J, Hellstrand K, Westin J, Nilsson S, et al
    Presence of interferon-lambda 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus.
    Scand J Gastroenterol. 2021 Jun 2:1-6. doi: 10.1080/00365521.2021.1922750.
    PubMed     Abstract available


    May 2021
  2. WALDENSTROM J, Kaberg M, Alanko Blome M, Widell A, et al
    Absence of interferon-lambda 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection.
    Scand J Gastroenterol. 2021 May 25:1-7. doi: 10.1080/00365521.2021.1925956.
    PubMed     Abstract available


  3. PIECHA F, Ganssler JM, Ozga AK, Wehmeyer MH, et al
    Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era.
    Scand J Gastroenterol. 2021 May 19:1-9. doi: 10.1080/00365521.2021.1915374.
    PubMed     Abstract available


    July 2020
  4. ALDURAYWISH A, Ragheb M, Taher I, Louis N, et al
    Prevalence, risk factors and impact of occult HCV infection on liver morbidity among haemodialysis patients: hospital-based cross-sectional study.
    Scand J Gastroenterol. 2020 Jul 10:1-7. doi: 10.1080/00365521.2020.1790649.
    PubMed     Abstract available


    May 2020
  5. KABERG M, Larsson SB, Jerkeman A, Nystedt A, et al
    High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder.
    Scand J Gastroenterol. 2020 May 1:1-7. doi: 10.1080/00365521.2020.1754456.
    PubMed     Abstract available


    September 2019
  6. SHRIDHAR GULATI R, Wimalanathan T, Norheim Andersen S, Isaksen K, et al
    The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients.
    Scand J Gastroenterol. 2019 Sep 3:1-4. doi: 10.1080/00365521.2019.1643403.
    PubMed     Abstract available


    August 2019
  7. KJELLIN M, Kileng H, Akaberi D, Palanisamy N, et al
    Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway.
    Scand J Gastroenterol. 2019 Aug 19:1-9. doi: 10.1080/00365521.2019.1652846.
    PubMed     Abstract available


    July 2019
  8. WELLHONER F, Doscher N, Tergast TL, Vital M, et al
    The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients.
    Scand J Gastroenterol. 2019 Jul 30:1-9. doi: 10.1080/00365521.2019.1647280.
    PubMed     Abstract available


    May 2019
  9. GAYAM V, Tiongson B, Mandal AK, Garlapati P, et al
    Real-world study of hepatitis C treatment with direct-acting antivirals in patients with drug abuse and opioid agonist therapy.
    Scand J Gastroenterol. 2019 May 23:1-10. doi: 10.1080/00365521.2019.1617893.
    PubMed     Abstract available


    March 2019
  10. KABERG M, Edgren E, Hammarberg A, Weiland O, et al
    Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange - evaluated with liver elasticity.
    Scand J Gastroenterol. 2019 Mar 23:1-9. doi: 10.1080/00365521.2019.1580764.
    PubMed     Abstract available


    January 2019
  11. YUYUN D, Zhihua T, Haijun W, Zhaoping L, et al
    Predictive value of the red blood cell distribution width-to-platelet ratio for hepatic fibrosis.
    Scand J Gastroenterol. 2019;54:81-86.
    PubMed     Abstract available


    November 2018
  12. KILENG H, Kjellin M, Akaberi D, Bergfors A, et al
    Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
    Scand J Gastroenterol. 2018 Nov 5:1-7. doi: 10.1080/00365521.2018.1511824.
    PubMed     Abstract available


    August 2018
  13. PERRELLA A, Izzi A, Punzi R, Adinolfi E, et al
    Late HCC onset after direct antiviral agents therapy in patients with sustained virological response: do we need to reconsider their efficacy according to long term follow-up?
    Scand J Gastroenterol. 2018;53:1025-1026.
    PubMed    


    July 2018
  14. LUND LAURSEN T, Brockner Siggard C, Kazankov K, Damgaard Sandahl T, et al
    Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
    Scand J Gastroenterol. 2018 Jul 10:1-8. doi: 10.1080/00365521.2018.1481996.
    PubMed     Abstract available


  15. ZUBKIN ML, Abdurakhmanov DT, Sagalova OI, Bakulin IG, et al
    Persistent mixed cryoglobulinemia after successful antiviral treatment of chronic hepatitis C virus infection: What's the next?
    Scand J Gastroenterol. 2018 Jul 2:1-2. doi: 10.1080/00365521.2018.1477988.
    PubMed    


    June 2018
  16. MILLBOURN C, Psaros Einberg A, Lindh G, Hokeberg I, et al
    Prevalence and outcome of post-transfusion hepatitis C acquired at different ages and detected in look-back screening.
    Scand J Gastroenterol. 2018 Jun 18:1-6. doi: 10.1080/00365521.2018.1476911.
    PubMed     Abstract available


    May 2018
  17. CARVALHO JR, Velosa J, Serejo F
    Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.
    Scand J Gastroenterol. 2018 May 20:1-7. doi: 10.1080/00365521.2018.1473486.
    PubMed     Abstract available


  18. SOLUND C, Hallager S, Pedersen MS, Fahnoe U, et al
    Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.
    Scand J Gastroenterol. 2018 May 2:1-8. doi: 10.1080/00365521.2018.1467963.
    PubMed     Abstract available


    January 2018
  19. BARTH C, Neusser S, Biermann J, Wasem J, et al
    Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting.
    Scand J Gastroenterol. 2018;53:76-82.
    PubMed     Abstract available


    October 2017
  20. HANSEN JF, Juul Nielsen M, Nystrom K, Leeming DJ, et al
    PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C.
    Scand J Gastroenterol. 2017 Oct 25:1-5. doi: 10.1080/00365521.2017.1392596.
    PubMed     Abstract available


    July 2017

  21. Correction to: Castedal et al., IFN-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Scand J Gastroenterol. 2017 Jul 13:1. doi: 10.1080/00365521.2017.1354499.
    PubMed    


    May 2017
  22. MARIA C, Michael S, Susanne C, Catarina S, et al
    INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Scand J Gastroenterol. 2017;52:585-588.
    PubMed     Abstract available


    October 2016
  23. ZHU H, Wu J, Shen X
    Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    July 2016
  24. MURUNGA E, Andersson M, Rensburg Cv
    Autoimmune hepatitis: a manifestation of immune reconstitution inflammatory syndrome in HIV infected patients?
    Scand J Gastroenterol. 2016;51:814-8.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: